Clinical and Laboratory Features of 16 Chinese VEXAS Syndrome Patients

16 male VEXAS syndrome patients were identified from a retrospective analysis of 4512 patients with hematologic abnormalities at a Chinese academic hospital between June 2023 and July 2024. The dataset, authored by Xiang Ren and last updated in April 2026, profiles patient demographics, clinical presentations, bone marrow findings, and UBA1 gene mutation variants.

Use Cases

• Characterizing the clinical spectrum of VEXAS syndrome based on reported symptoms like anemia, lymphopenia, skin lesions, and chondritis.
• Analyzing the prevalence and types of UBA1 gene mutations based on the reported canonical and infrequent variants.
• Investigating associations between hematological abnormalities (e.g., CCUS, MDS, MGUS) and systemic inflammation based on the described patient phenotypes.
• Studying treatment response patterns based on the reported use of corticosteroids, immunosuppressants, androgens, and erythropoiesis-stimulating agents.

Strengths

• Focuses on a recently characterized and poorly studied disorder (VEXAS syndrome) in a specific population.
• Includes specific clinical and genetic findings for 16 patients, such as median age (61.5 years) and mutation prevalence (81.3% with canonical UBA1 variants).
• Data is derived from a sizable screening cohort of 4512 patients at a single academic center.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small (21.6 KB), indicating limited scope and sample size.

Provenance

Source

figshare, author Xiang Ren.

Collection Method

Retrospective analysis of consecutive patients at a Chinese academic hospital.

Time Range

Patient data collected between June 2023 and July 2024.

Freshness

Last updated 2026-04-16 05:19:14; freshness should be verified.

Geography

China (single-center study).